Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Government health plans in the U.S. provide significant coverage for new weight-loss drugs, overshadowing private insurers.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Novo Nordisk is an attractive growth stock to buy and hold because the company is still in the early stages of rolling out ...

Doctors Without Borders (MSF) and organisations representing people with diabetes picketed outside the offices of insulin ...